Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actual Use Study of Ibuprofen 600 mg ER/IR Tablets in At-Risk Consumers
NCT03722238Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibuprofen in pain, sponsored by Pfizer. Primary endpoint: Percentage of Participants Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period. Started Dec 2018; status: terminated.
02
Drugs
ibuprofen
03
Conditions
pain
Beyond the preview
Go deeper on NCT03722238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722238.